NCT04539912

Brief Summary

Objective: To compare the clinical efficacy of angulated screw-retained and cemented single implant crowns(SIC) in esthetic region. Methods/Design: The study was a prospective, single center, randomized controlled clinical trial. Patients with the needs of single tooth restoration in esthetics region were recruited from Oct. 2018 to Aug. 2019. Sixty patients were enrolled in the present study and they were randomly assigned into two groups: angulated screw-retained group(AG, 30 patients) and cemented group (CG,30 patients). Clinical and radiological evaluations were performed on the day of final crowns delivery and 12 months later. Implant survival rate, marginal bone loss(MBL), pro-inflammatory cytokinesin peri-implant crevicular fluid (PICF)(TNF-α, IL-6), mechanical complications, peri-implant conditions(mPI, PD, BOP%), pink esthetics score/white esthetics score (PES/ WES) and patients satisfaction were assessed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 1, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 7, 2020

Completed
Last Updated

September 7, 2020

Status Verified

September 1, 2020

Enrollment Period

1 year

First QC Date

September 1, 2020

Last Update Submit

September 4, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Marginal bone loss

    Peri-apical radiographs with paralleling technique wereperformed on the day offinal restorations delivery and 1-year visit. Implant length was used as calibration reference. The distance between restoration margin and the most coronal level of implant-bone contactwas recorded. Final result was calculated as themean value of the mesial and distal sites

    1year

Secondary Outcomes (8)

  • Survival rate.

    1 year

  • Pro-inflammatory cytokinesin peri-implant crevicular fluid (PICF)

    1 year

  • Mechanical complications

    1 year

  • pocket probing depth(PD)

    1 year

  • PES/WES

    1 year

  • +3 more secondary outcomes

Study Arms (2)

angulated screw-retained group(AG)

EXPERIMENTAL
Device: angulated screw retained crown

cemented group (CG)

ACTIVE COMPARATOR
Device: cemented crown

Interventions

ASC abutment was used in AG;

angulated screw-retained group(AG)

prefabricated Ti abutment was used in CG

cemented group (CG)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \) age≥18;
  • \) Single dental implant in the esthetic region;
  • \) adjacent to natural teeth;
  • \) absence of oral mucosal disease and oral infection;
  • )implants withconical connection (Nobel Active, Nobel Biocare® or NobelReplace Conical Connection, Nobel Biocare®);
  • )patients with the willingness of all-ceramic permanent restorations.

You may not qualify if:

  • )Multiple implants in the esthetic region, or the restoration is a bridge;
  • )Heavy smokers (\>10 cigarettes/day);
  • \) the angle between implant axis and restoration axis\>25°;
  • \) uncontrolled periodontitis;
  • \) with systematic diseases that may affect implant therapy, such as uncontrolled diabetes mellitus (Fasting blood-glucose\>7.2mmol/L, Glycosylated hemoglobin \>7%), current intake of bisphosphonates (treatment for malignancy), pregnant(or plan to get pregnant), with history of radiation therapy in head and neck region;
  • \) Unwilling to participate in the present study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jun-Yu Shi

Shanghai, Shanghai Municipality, 200011, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 1, 2020

First Posted

September 7, 2020

Study Start

August 1, 2018

Primary Completion

August 1, 2019

Study Completion

August 1, 2020

Last Updated

September 7, 2020

Record last verified: 2020-09

Locations